Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT0A3Y)

• Drug Name: Etrasimod Drug Info
• Synonyms: APD-334; S1P1 receptor agonists (autoimmune diseases), Arena Pharmaceuticals

Indication

Disease Entry	ICD 11	Status	REF
Ulcerative colitis	DD71	Approved	[1]
Autoimmune diabetes	5A10	Phase 2	[2]
Pyoderma gangrenosum	EB21	Phase 2	[3]

• Cross-matching ID:
  PubChem CID: 44623998
  CAS Number: CAS 1206123-37-6
  TTD Drug ID: DMT0A3Y

Molecule-Related Drug Atlas

Drug(s) Targeting Sphingosine-1-phosphate receptor 1 (S1PR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Siponimod	DM2R86O	Multiple sclerosis	8A40	Approved	[5]
Fingolimod	DM5JVAN	Multiple sclerosis	8A40	Approved	[6]
Ozanimod	DMT6AM2	Multiple sclerosis	8A40	Approved	[7]
Ponesimod	DMEAOYJ	Multiple sclerosis	8A40	Approved	[8]
MT-1303	DMSE9TH	Crohn disease	DD70	Phase 2	[9]
ONO-4641	DMLUM3Y	Rheumatoid arthritis	FA20	Phase 2	[10]
KRP-203	DMOW9X2	Cutaneous lupus erythematosus	EB5Z	Phase 2	[10]
VTX-002	DMZ8Z5A	Ulcerative colitis	DD71	Phase 2	[11]
CBP-307	DM3TH6Y	Ulcerative colitis	DD71	Phase 2	[12]
Sphingosine-1-phosphate	DMJCQKA	Acne vulgaris	ED80	Phase 1	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sphingosine-1-phosphate receptor 1 (S1PR1)	TT9JZCK	S1PR1_HUMAN	Agonist	[4]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216956
• [2] ClinicalTrials.gov (NCT02447302) Safety and Efficacy of APD334 in Patients With Ulcerative Colitis. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [6] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [9] Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
• [10] Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
• [11] Clinical pipeline report, company report or official report of Ventyx Biosciences
• [12] Clinical pipeline report, company report or official report of Connect Biopharma
• [13] Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2520-4.